A citation-based method for searching scientific literature

Xia Wang, Peilin Zheng, Gan Huang, Lin Yang, Zhiguang Zhou. Clin Exp Med 2018
Times Cited: 14







List of co-cited articles
49 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Low DPP4 expression and activity in multiple sclerosis.
Marta Tejera-Alhambra, Armanda Casrouge, Clara de Andrés, Rocío Ramos-Medina, Bárbara Alonso, Janet Vega, Matthew L Albert, Silvia Sánchez-Ramón. Clin Immunol 2014
21
21


Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).
Takuya Awata, Akira Shimada, Taro Maruyama, Yoichi Oikawa, Nobuyuki Yasukawa, Susumu Kurihara, Yumi Miyashita, Masako Hatano, Yuichi Ikegami, Masafumi Matsuda,[...]. Diabetes Ther 2017
24
21

Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults.
E Rapti, S Karras, M Grammatiki, A Mousiolis, X Tsekmekidou, E Potolidis, P Zebekakis, M Daniilidis, K Kotsa. Endocrinol Diabetes Metab Case Rep 2016
21
21

Latent autoimmune diabetes in adults (LADA) should be less latent.
S Fourlanos, F Dotta, C J Greenbaum, J P Palmer, O Rolandsson, P G Colman, L C Harrison. Diabetologia 2005
197
14

Identification of a distinct phenotype of elderly latent autoimmune diabetes in adults: LADA China Study 8.
Xiaohong Niu, Shuoming Luo, Xia Li, Zhiguo Xie, Yufei Xiang, Gan Huang, Jian Lin, Lin Yang, Zhenqi Liu, Xiangbing Wang,[...]. Diabetes Metab Res Rev 2019
13
15

Latent Autoimmune Diabetes in Adults: Current Status and New Horizons.
Paolo Pozzilli, Silvia Pieralice. Endocrinol Metab (Seoul) 2018
21
14

Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Weijia Xie, Xiaoxiao Song, Zhenjie Liu. Vascul Pharmacol 2018
12
16


Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.
J Béné, G Moulis, I Bennani, M Auffret, P Coupe, S Babai, D Hillaire-Buys, J Micallef, S Gautier. Br J Dermatol 2016
88
14

Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
H Horikawa, Y Kurihara, T Funakoshi, N Umegaki-Arao, H Takahashi, A Kubo, A Tanikawa, N Kodani, Y Minami, S Meguro,[...]. Br J Dermatol 2018
29
14

Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
Irene García-Díez, Marta Ivars-Lleó, Daniel López-Aventín, Norito Ishii, Takashi Hashimoto, Pilar Iranzo, Ramon M Pujol, Agustín España, Josep E Herrero-Gonzalez. Int J Dermatol 2018
27
14

Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study.
Outi Varpuluoma, Anna-Kaisa Försti, Jari Jokelainen, Miia Turpeinen, Markku Timonen, Laura Huilaja, Kaisa Tasanen. J Invest Dermatol 2018
64
14

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Seoyoung C Kim, Sebastian Schneeweiss, Robert J Glynn, Michael Doherty, Allison B Goldfine, Daniel H Solomon. Ann Rheum Dis 2015
56
14

Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Chika Chijiwa, Shintaro Takeoka, Masahiro Kamata, Mihoko Tateishi, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi,[...]. J Dermatol 2018
26
14

Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
Michael Benzaquen, Luca Borradori, Philippe Berbis, Simone Cazzaniga, René Valero, Marie-Aleth Richard, Laurence Feldmeyer. J Am Acad Dermatol 2018
76
14

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
Devin Abrahami, Antonios Douros, Hui Yin, Oriana Hoi Yun Yu, Christel Renoux, Alain Bitton, Laurent Azoulay. BMJ 2018
49
14

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
Satoshi Yoshiji, Takaaki Murakami, Shin-Ichi Harashima, Rie Ko, Riko Kashima, Daisuke Yabe, Masahito Ogura, Kentaro Doi, Nobuya Inagaki. J Diabetes Investig 2018
23
14

Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature.
Amy Attaway, Tracey L Mersfelder, Sakshi Vaishnav, Joanne K Baker. J Dermatol Case Rep 2014
50
14

Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases.
Efi Pasmatzi, Alexandra Monastirli, John Habeos, Sophia Georgiou, Dionysios Tsambaos. Diabetes Care 2011
51
14

Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
Yohei Kawaguchi, Risa Shimauchi, Nobuhiro Nishibori, Kiyohito Kawashima, So Oshitani, Atsushi Fujiya, Taiga Shibata, Norimi Ohashi, Kentaro Izumi, Wataru Nishie,[...]. J Diabetes Investig 2019
30
14

Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.
K Skandalis, M Spirova, G Gaitanis, A Tsartsarakis, I D Bassukas. J Eur Acad Dermatol Venereol 2012
86
14

Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.
Outi Varpuluoma, Anna-Kaisa Försti, Jari Jokelainen, Miia Turpeinen, Markku Timonen, Kaisa Tasanen, Laura Huilaja. J Am Acad Dermatol 2018
28
14

Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.
Joshua A Radel, Danielle N Pender, Sachin A Shah. Ann Pharmacother 2019
8
25


CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently.
C Klemann, J Schade, R Pabst, S Leitner, J Stiller, S von Hörsten, M Stephan. Clin Exp Immunol 2009
29
14

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Mika Nabeno, Fumihiko Akahoshi, Hiroyuki Kishida, Ikuko Miyaguchi, Yoshihito Tanaka, Shinichi Ishii, Takashi Kadowaki. Biochem Biophys Res Commun 2013
138
14

Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis.
Hasan Ulusoy, Ayhan Kamanli, Necip Ilhan, Omer Kuru, Sule Arslan, Gokhan Alkan, Salih Ozgocmen. Rheumatol Int 2012
18
14

CD26 expression is down-regulated on CD8+ T cells in patients with Hashimoto's thyroiditis.
Yalei Liu, Yuan Li, Yan Gong, Nan Yu, Yang Zhang, Ran You, Chenxue Qu, Guizhi Lu, Youyuan Huang, Ying Gao,[...]. Int Immunopharmacol 2018
6
33

Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus.
Hiroshi Kobayashi, Osamu Hosono, Tsuneyo Mimori, Hiroshi Kawasaki, Nam Hoang Dang, Hirotoshi Tanaka, Chikao Morimoto. J Rheumatol 2002
52
14

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
14


Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.
Nathalie Busso, Nicolai Wagtmann, Christian Herling, Veronique Chobaz-Péclat, Angelika Bischof-Delaloye, Alexander So, Eric Grouzmann. Am J Pathol 2005
158
14

Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes.
Saeko Osawa, Dan Kawamori, Naoto Katakami, Mitsuyoshi Takahara, Fumie Sakamoto, Takashi Katsura, Tetsuyuki Yasuda, Hideaki Kaneto, Munehide Matsuhisa, Taka-Aki Matsuoka,[...]. Diabetes Res Clin Pract 2016
17
14

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Qixian Wang, Min Long, Hua Qu, Rufei Shen, Rui Zhang, Jing Xu, Xin Xiong, Hui Wang, Hongting Zheng. J Diabetes Res 2018
19
14

Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes.
Tímea Varga, Anikó Somogyi, Gábor Barna, Barna Wichmann, Géza Nagy, Károly Rácz, László Selmeci, Gábor Firneisz. Pathol Oncol Res 2011
39
14

Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: An experimental study.
Urmila Anil Kagal, Netravathi Basavaraj Angadi, Somnath Mallikarjun Matule. Int J Appl Basic Med Res 2017
14
14

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
73
14

Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.
Marcelo Maia Pinheiro, Caroline Lais Stoppa, Claudete Justina Valduga, Cristina Eunice Okuyama, Renata Gorjão, Regina Mara Silva Pereira, Susana Nogueira Diniz. Eur J Pharm Sci 2017
39
14

Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.
André J Tremblay, Benoît Lamarche, Carolyn F Deacon, S John Weisnagel, Patrick Couture. Metabolism 2014
82
14



GIP and GLP-1, the two incretin hormones: Similarities and differences.
Yutaka Seino, Mitsuo Fukushima, Daisuke Yabe. J Diabetes Investig 2010
273
14

Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial.
Ingrid K Hals, Hanne Fiskvik Fleiner, Nina Reimers, Marianne C Astor, Karin Filipsson, Zuheng Ma, Valdemar Grill, Anneli Björklund. Diabetes Obes Metab 2019
11
18

C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
Odd Erik Johansen, Bernhard O Boehm, Valdemar Grill, Peter A Torjesen, Sudipta Bhattacharya, Sanjay Patel, Kristiane Wetzel, Hans-Juergen Woerle. Diabetes Care 2014
42
14



Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
A D Dobrian, Q Ma, J W Lindsay, K A Leone, K Ma, J Coben, E V Galkina, J L Nadler. Am J Physiol Endocrinol Metab 2011
105
14

Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).
R Buzzetti, P Pozzilli, R Frederich, N Iqbal, B Hirshberg. Diabetes Metab Res Rev 2016
32
14

Type 2 diabetes as an inflammatory disease.
Marc Y Donath, Steven E Shoelson. Nat Rev Immunol 2011
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.